Thomas Biegi: I had the honor of participating in a panel discussion during The Leukemia and Lymphoma Society’s event ‘TAP Into a Cure’
Thomas Biegi, Senior Vice President, Head of Corporate Affairs at MorphoSys, made the following post on LinkedIn:
“Earlier this month, I had the honor of participating in a panel discussion during The Leukemia & Lymphoma Society’s (LLS) event ‘TAP Into a Cure,’ which spotlights their Therapy Acceleration Program (TAP) and the vital role of venture philanthropy in advancing drug development for Blood Cancer patients.
I reflected on our longstanding partnership with LLS and TAP’s investment, sharing how this critical funding moved our promising BET inhibitor into phase 1 studies, and mapped out the path to where we are today.
Here are my key takeaways from the discussion:
𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗶𝘀 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝘁𝗼 𝗠𝗮𝘅𝗶𝗺𝗶𝘇𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 – When you combine scientific expertise with strategic investment, amazing things can happen. We’ve witnessed this firsthand in the development of our innovative therapies, tapping into the LLS for both funding as well as blood cancer knowledge and relationships to advance our science.
𝗠𝗮𝗸𝗲 𝗧𝗵𝗲𝘀𝗲 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗟𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 – As a sophisticated patient organization, LLS was an ideal partner for our efforts at the beginning and continues to be one now, as we have worked together throughout the development process. By working together for so long, we have a strong grasp of each other’s strengths and where we can best help the other.
𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗣𝗵𝗶𝗹𝗮𝗻𝘁𝗵𝗿𝗼𝗽𝘆 𝗵𝗮𝘀 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗪𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 – While these venture philanthropy programs have yielded impressive results in the U.S. in the past 30 years, this concept is relatively untapped in Europe and beyond. The global potential is undeniable, and we would leave so much potential untapped if we don’t find solutions for creative funding opportunities and venture therapy programs in other countries too.
I’m so grateful to LLS for the opportunity to contribute to this important conversation and looking forward to our continued partnership.”
Source: Thomas Biegi/LinkedIn
.